Effects of salicylate and phenobarbital on lymphocyte proliferation and function

John D. Gabourel, Gordon H. Davies, Marvin Rittenberg

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Salicylate inhibited the response of human peripheral lymphocytes to phytohemagglutinim (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), and X-irradiated allogeneic lymphocytes. In addition, salicylate suppressed the generation of cytotoxic lymphocytes (CL) in vitro. The effect was dose dependent with over 90% inhibition at 48 mg%. Once CL were generated, however, the drug had little effect on their ability to lyse target cells. Sodium salicylate also suppressed the proliferative response of parental mouse thymocytes adoptively transferred into lethally irradiated F1 hybrid recipients as assessed by splenic uptake of [125I] iododeoxyuridine. High-dose, chronic treatment of both thymocyte donors and recipients was necessary to effect a 20-60% suppression. Similar chronic treatment of mice depressed the number of splenic plaque-forming cells by 48-72% when assayed 4 days after primary challenge with sheep erythrocytes. On the contrary, we could find no effect of phenobarbital on the response to PHA, mixed lymphocyte culture, or on the generation of CL.

Original languageEnglish (US)
Pages (from-to)53-61
Number of pages9
JournalClinical Immunology and Immunopathology
Volume7
Issue number1
DOIs
StatePublished - 1977

Fingerprint

Salicylates
Phenobarbital
Lymphocytes
Thymocytes
Sodium Salicylate
Idoxuridine
Pokeweed Mitogens
Concanavalin A
Sheep
Erythrocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Effects of salicylate and phenobarbital on lymphocyte proliferation and function. / Gabourel, John D.; Davies, Gordon H.; Rittenberg, Marvin.

In: Clinical Immunology and Immunopathology, Vol. 7, No. 1, 1977, p. 53-61.

Research output: Contribution to journalArticle

Gabourel, John D. ; Davies, Gordon H. ; Rittenberg, Marvin. / Effects of salicylate and phenobarbital on lymphocyte proliferation and function. In: Clinical Immunology and Immunopathology. 1977 ; Vol. 7, No. 1. pp. 53-61.
@article{6c5acebb012f4bb8ba5c381ab1b01630,
title = "Effects of salicylate and phenobarbital on lymphocyte proliferation and function",
abstract = "Salicylate inhibited the response of human peripheral lymphocytes to phytohemagglutinim (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), and X-irradiated allogeneic lymphocytes. In addition, salicylate suppressed the generation of cytotoxic lymphocytes (CL) in vitro. The effect was dose dependent with over 90{\%} inhibition at 48 mg{\%}. Once CL were generated, however, the drug had little effect on their ability to lyse target cells. Sodium salicylate also suppressed the proliferative response of parental mouse thymocytes adoptively transferred into lethally irradiated F1 hybrid recipients as assessed by splenic uptake of [125I] iododeoxyuridine. High-dose, chronic treatment of both thymocyte donors and recipients was necessary to effect a 20-60{\%} suppression. Similar chronic treatment of mice depressed the number of splenic plaque-forming cells by 48-72{\%} when assayed 4 days after primary challenge with sheep erythrocytes. On the contrary, we could find no effect of phenobarbital on the response to PHA, mixed lymphocyte culture, or on the generation of CL.",
author = "Gabourel, {John D.} and Davies, {Gordon H.} and Marvin Rittenberg",
year = "1977",
doi = "10.1016/0090-1229(77)90029-0",
language = "English (US)",
volume = "7",
pages = "53--61",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of salicylate and phenobarbital on lymphocyte proliferation and function

AU - Gabourel, John D.

AU - Davies, Gordon H.

AU - Rittenberg, Marvin

PY - 1977

Y1 - 1977

N2 - Salicylate inhibited the response of human peripheral lymphocytes to phytohemagglutinim (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), and X-irradiated allogeneic lymphocytes. In addition, salicylate suppressed the generation of cytotoxic lymphocytes (CL) in vitro. The effect was dose dependent with over 90% inhibition at 48 mg%. Once CL were generated, however, the drug had little effect on their ability to lyse target cells. Sodium salicylate also suppressed the proliferative response of parental mouse thymocytes adoptively transferred into lethally irradiated F1 hybrid recipients as assessed by splenic uptake of [125I] iododeoxyuridine. High-dose, chronic treatment of both thymocyte donors and recipients was necessary to effect a 20-60% suppression. Similar chronic treatment of mice depressed the number of splenic plaque-forming cells by 48-72% when assayed 4 days after primary challenge with sheep erythrocytes. On the contrary, we could find no effect of phenobarbital on the response to PHA, mixed lymphocyte culture, or on the generation of CL.

AB - Salicylate inhibited the response of human peripheral lymphocytes to phytohemagglutinim (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), and X-irradiated allogeneic lymphocytes. In addition, salicylate suppressed the generation of cytotoxic lymphocytes (CL) in vitro. The effect was dose dependent with over 90% inhibition at 48 mg%. Once CL were generated, however, the drug had little effect on their ability to lyse target cells. Sodium salicylate also suppressed the proliferative response of parental mouse thymocytes adoptively transferred into lethally irradiated F1 hybrid recipients as assessed by splenic uptake of [125I] iododeoxyuridine. High-dose, chronic treatment of both thymocyte donors and recipients was necessary to effect a 20-60% suppression. Similar chronic treatment of mice depressed the number of splenic plaque-forming cells by 48-72% when assayed 4 days after primary challenge with sheep erythrocytes. On the contrary, we could find no effect of phenobarbital on the response to PHA, mixed lymphocyte culture, or on the generation of CL.

UR - http://www.scopus.com/inward/record.url?scp=0017337863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017337863&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(77)90029-0

DO - 10.1016/0090-1229(77)90029-0

M3 - Article

C2 - 15750

AN - SCOPUS:0017337863

VL - 7

SP - 53

EP - 61

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -